How the treatment of AML will change

Mary Frances McMullin

Mary Frances McMullin, MD of Belfast City Hospital, Belfast, UK discusses targeted therapy and immunotherapy for acute myeloid leukemia (AML) held at the 2017 British Society for Haematology (BSH) Annual Scientific Meeting in Brighton, UK. Prof. McMullin explains that she was part of a discussion at BSH on targeted therapy and immunotherapy for AML. We are in the era of molecular medicine as our understanding of mutations underlying disease is improving and she explains that this may change the treatment of AML.

Share this video  
Similar topics
Related videos
1:12
FLT3 inhibitors in the treatment of AML
Farhad Ravandi
1:57
Breakthroughs in the treatment of elderly patients with AML
Farhad Ravandi
4:14
Future therapies for AML: bispecifics and small molecule inhibitors
Farhad Ravandi
1:32
IDH inhibitors for AML and MDS
Eunice Wang
3:41
Computational methods are the future of biological research
Dominique Bonnet
Acute Myeloid Leukemia
BSH 2017
Interview
29th March 2017
More from Mary Frances McMullin
Progress in MPNs
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals